Table 2.

Mean change of d-dimer, IL-6 and hs-CRP

Endpoint	Mean % [95%CI] change		Log10 transformed data
	placebo	vorapaxar	Difference between treatment groups†	p-value
Baseline to average of week 8·12
*d-dimer (ng/mL)	−8·5 [−18·4, 2·5]	−10·8 [−23·1, 3·4]	−0·02 [−0·10, 0·05]	0·56
IL-6 (pg/mL)	−11·6 [−29·1, 10·3]	12·6 [−15·6, 50·4]	0·08 [−0·06, 0·22]	0·25
hs-CRP (μg/mL)	−15·7 [−40·9, 20·2]	−0·02 [−41·3, 70·2]	0·02 [−0·20, 0·24]	0·84
Baseline to week 8
d-dimer (ng/mL)	−10·7 [−19·5, 2·0]	−12·5 [−25·0, 2·1]	−0·03 [−0·10, 0·05]	0·52
IL-6 (pg/mL)	−14·3 [−33·4, 10·2]	−1·1 [−27·2, 34·4]	0·04 [−0·11, 0·19]	0·63
hs-CRP (μg/m/L)	−14·2 [−41·9, 26·9]	−0·5 [−44·8, 79·4]	0·02 [−0·24, 0·27]	0·91
Baseline to week 12
d-dimer (ng/mL)	−8·8 [−19·4, 3·2]	−10·2 [−22·9, 4·5]	−0·02 [−0·09, 0·06]	0·64
IL-6 (pg/mL)	−13·3 [−29·6, 6·9]	10·4 [−16·0, 45·1]	0·08 [−0·05, 0·21]	0·22
hs-CRP (μg/mL)	−28·2 [−50·5, 4·2]	−24·3 [−50·9, 16·5]	−0·02 [−0·21, 0·16]	0·79
Week 12 to week 18
d-dimer (ng/mL)	8·0 [−6·9, 25·2]	8·9 [−5·0, 24·9]	0·003 [−0·08, 0·09]	0·95
IL-6 (pg/mL)	−8·2 [−21·5, 7·5]	−1·9 [−29·1, 35·7]	0·03 [−0·12, 0·18]	0·70
hs-CRP (μg/mL)	11·6 [−14·4, 45·3]	24·6 [−14·7, 82·1]	0·07 [−0·13, 0·25]	0·53

^*study primary endpoint

^†Linear regression for change (log10) modelled against treatment and baseline outcome variable.